Literature DB >> 8419638

The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.

A B Kulkarni1, M Connors, C Y Firestone, H C Morse, B R Murphy.   

Abstract

Previous studies demonstrated that the pulmonary resistance to respiratory syncytial virus (RSV) challenge induced by immunization with a recombinant vaccinia virus expressing the M2 protein of RSV (vac-M2) was significantly greater 9 days after immunization than at 28 days and was mediated predominantly by CD8+ T cells. In this study, we have extended these findings and sought to determine whether the level of CD8+ cytotoxic T-lymphocyte (CTL) activity measured in vitro correlates with the resistance to RSV challenge in vivo. Three lines of evidence documented an association between the presence of pulmonary CTL activity and resistance to RSV challenge. First, vac-M2 immunization induced pulmonary CD8+ CTL activity and pulmonary resistance to RSV infection in BALB/c (H-2d) mice, whereas significant levels of pulmonary CTL activity and resistance to RSV infection were not seen in BALB.K (H-2k) or BALB.B (H-2b) mice. Second, pulmonary CD8+ CTL activity was not induced by infection with other vaccinia virus-RSV recombinants that did not induce resistance to RSV challenge. Third, the peak of pulmonary CTL activity correlated with the peak of resistance to RSV replication (day 6), with little resistance being observed 45 days after immunization. An accelerated clearance of virus was not observed when mice were challenged with RSV 45 days after immunization with vac-M2. The results indicate that resistance to RSV induced by immunization with vac-M2 is mainly mediated by primary pulmonary CTLs and that this resistance decreases to very low levels within 2 months following immunization. The implications for inclusion of CTL epitopes into RSV vaccines are discussed in the context of these observations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419638      PMCID: PMC237459     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.

Authors:  C Fayolle; E Deriaud; C Leclerc
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

2.  Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.

Authors:  L S Klavinskis; J L Whitton; E Joly; M B Oldstone
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

3.  Primary pulmonary murine cytotoxic T lymphocyte specificity in respiratory syncytial virus pneumonia.

Authors:  R Gupta; J W Yewdell; R A Olmsted; P L Collins; J R Bennink
Journal:  Microb Pathog       Date:  1990-07       Impact factor: 3.738

4.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.

Authors:  M Del Val; H J Schlicht; T Ruppert; M J Reddehase; U H Koszinowski
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

5.  Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection.

Authors:  J J Anderson; J Norden; D Saunders; G L Toms; R Scott
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

6.  Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus.

Authors:  A Endo; S Itamura; H Iinuma; S Funahashi; H Shida; F Koide; K Nerome; A Oya
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

7.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

8.  Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication.

Authors:  J A Nicholas; K L Rubino; M E Levely; A L Meyer; P L Collins
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

9.  Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens.

Authors:  R G Webster; Y Kawaoka; J Taylor; R Weinberg; E Paoletti
Journal:  Vaccine       Date:  1991-05       Impact factor: 3.641

10.  Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.

Authors:  M Connors; P L Collins; C Y Firestone; B R Murphy
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  30 in total

1.  Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.

Authors:  Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract.

Authors:  Peter M Gray; Subhashini Arimilli; Ellen M Palmer; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  CD8+ T cells can mediate almost complete short-term and partial long-term immunity to rotavirus in mice.

Authors:  M A Franco; C Tin; H B Greenberg
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.

Authors:  Alexander Kotelkin; Igor M Belyakov; Lijuan Yang; Jay A Berzofsky; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Primary cytotoxic T-cell responses to bovine respiratory syncytial virus in calves.

Authors:  R M Gaddum; R S Cook; L H Thomas; G Taylor
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

7.  Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.

Authors:  Alexander Bukreyev; Igor M Belyakov; Gregory A Prince; Kevin C Yim; Katie K Harris; Jay A Berzofsky; Peter L Collins
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection.

Authors:  Deepthi Kolli; Efthalia L Bataki; Leanne Spetch; Antonieta Guerrero-Plata; Alan M Jewell; Pedro A Piedra; Gregg N Milligan; Roberto P Garofalo; Antonella Casola
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.

Authors:  A B Kulkarni; H C Morse; J R Bennink; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.